<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1768">
  <stage>Registered</stage>
  <submitdate>30/11/2007</submitdate>
  <approvaldate>30/11/2007</approvaldate>
  <nctid>NCT00566657</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions</studytitle>
    <scientifictitle>A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions</scientifictitle>
    <utrn />
    <trialacronym>TAMARIS</trialacronym>
    <secondaryid>2006-006277-24</secondaryid>
    <secondaryid>EFC6145</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Vascular Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - riferminogene pecaplasmid
Other interventions - Placebo (for riferminogene pecaplasmid)

Experimental: Riferminogene pecaplasmid - 4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals

Placebo Comparator: Placebo - 4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals


Other interventions: riferminogene pecaplasmid
Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid
Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated

Other interventions: Placebo (for riferminogene pecaplasmid)
Formulation: 5 ml glass vials containing 2,5 ml placebo
Route: IM injection of 2.5 mL in the ischemic leg to be treated

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to major amputation of the treated leg or death from any cause, whichever comes first</outcome>
      <timepoint>From randomization up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first major amputation of the treated leg</outcome>
      <timepoint>From randomization up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to death from any cause</outcome>
      <timepoint>From randomization up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with adverse events as a measure of safety</outcome>
      <timepoint>From 1st treatment administration up to death, or the earliest of Day 360 or last contact/assessment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Having peripheral artery disease at the stage of Critical Limb Ischemia (CLI) with
             skin lesions (either ulcer(s) or gangrene);

          -  With objective evidence of CLI such as ankle systolic pressure &lt;70 mmHg and/or toe
             systolic pressure &lt;50 mmHg or transcutaneous oxygen pressure (TcPO2) &lt;30 mmHg;

          -  Unsuitable for standard revascularization of his/her peripheral arterial disease;

          -  Having a negative screening for cancer.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous major amputation on the leg to be treated or planned major amputation within
             the first month following randomization;

          -  Known Buerger's disease;

          -  Successful lower extremity revascularization procedure within 3 months prior
             randomization;

          -  Uncontrolled blood pressure defined as systolic blood pressure (SBP) =180 mmHg or
             diastolic blood pressure (DBP) =110 mmHg despite adequate antihypertensive treatment;

          -  Acute cardiovascular events within 3 months prior to randomization;

          -  Active proliferative retinopathy and severe macular oedema;

          -  Previous or current history of malignant disease within the past 5 years;

          -  Previous treatment with systemic angiogenic factors or with stem cells therapy;

          -  Pregnant or breast-feeding woman or woman of childbearing potential not protected by
             an effective contraceptive method of birth control. Man not following effective
             contraceptive method with his partner of childbearing potential during the course of
             the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>525</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Sanofi-Aventis Administrative Office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos AIres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belarus</country>
      <state>Minsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Horsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tatari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Causeway Bay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Bromma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary objective is to demonstrate the superiority of riferminogene pecaplasmid
      (XRP0038/NV1FGF) over placebo in the prevention of major amputation above the ankle of the
      treated leg or of death from any cause, whichever comes first, in critical limb ischemia
      (CLI) patients with skin lesions.

      Secondary objectives are to evaluate:

        -  The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to major
           amputation;

        -  The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to death;

        -  The safety of riferminogene pecaplasmid in the study population.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00566657</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>